CLENE INC

CLNN stock represents shares of Clene Inc., a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The stock trades on the Nasdaq Capital Market under the ticker CLNN. As a small-cap company, its share price and market value can be volatile based on clinical trial outcomes, regulatory updates, and financing activities.

Recent performance for CLNN can be found in the price chart and performance metrics on this page, which show daily changes and longer-term trends. As a clinical-stage biotech, the stock often reacts to news about trials, partnerships, or financing. For the most current price, volume, and percentage moves, refer to the live data displayed above.

Because CLNN is a clinical-stage company with no approved products generating revenue, traditional valuation metrics like P/E are not meaningful. Investors often assess valuation based on the company's pipeline, cash position, and potential market opportunity. You can review the latest financial statements and analyst estimates on this page for context.

To buy CLNN stock, open a brokerage account that offers access to U.S. markets. Search for the ticker CLNN, then place a market or limit order during regular trading hours. Some brokers also allow extended-hours trading. Ensure you understand order types and any applicable fees before trading.

CLNN does not currently pay dividends. As a clinical-stage biopharmaceutical company, it typically reinvests any available capital into research and development rather than returning cash to shareholders. For the most up-to-date dividend information, check the dividend section on this page or the company's investor relations website.

Key risks for CLNN include clinical trial failures, regulatory delays, and the need for additional financing, which can dilute existing shareholders. As a small-cap biotech, its stock may be volatile and less liquid. Competitive pressures and reliance on key personnel also pose risks. Review the company's SEC filings for a detailed risk discussion.